The Investor Relations website contains information about ImmunoGen, Inc.'s business for stockholders, potential investors, and financial analysts.
People also ask
What happened to IMGN stock?
Who owns ImmunoGen?
Is ImmunoGen a good investment?
What is IMGN stock?
ImmunoGen IR Menu. Investors · Press Releases · Events ... --(BUSINESS WIRE)--Feb. 1, 2024-- ImmunoGen, Inc. , (Nasdaq: IMGN) ... ImmunoGen Announces Webcast of ...
Nov 30, 2023 · ImmunoGen's Phase 1 asset, IMGN ... The call will be webcast through AbbVie's Investor Relations website at investors.abbvie.com. ... website at www ...
Sep 18, 2023 · Ms. White has over 20 years of international experience in corporate finance, strategic partnering, accounting, and investor relations. She ...
Oct 19, 2023 · WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 19, 2023-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates ( ...
Feb 25, 2022 · The Investor Relations website contains information about ImmunoGen, Inc.'s business for stockholders, potential investors, and financial ...
Nov 3, 2023 · Today's conference is being recorded. At this time, I'd like to turn the call over to Anabel Chan, Head of Investor Relations. Please go ahead.
ImmunoGen, Inc. (IMGN) CEO Mark Enyedy on Q2 2022 Results - Earnings Call Transcript · SA TranscriptsFri, Jul. 29, 2022. ImmunoGen (IMGN) Investor Presentation ...
INVESTOR RELATIONS AND MEDIA. . ImmunoGen. Courtney O'Konek. 781-895-0600. courtney.okonek@immunogen.com. . OR. . FTI Consulting. Robert Stanislaro. 212-850- ...
Rating
(711,576)
Immunogen (IMGN) stock investors activity – investors allocate an average of 4.95% to IMGN, based on 711576 active investor portfolios.